APA (7th ed.) Citation

LE, M., AJ, P., BL, M., PW, B., A, C., HP, E., & D, B. (2020). Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM. Clinical lymphoma, myeloma & leukemia, 20(1), 24. https://doi.org/10.1016/j.clml.2019.09.615

Chicago Style (17th ed.) Citation

LE, Merz, Perissinotti AJ, Marini BL, Burke PW, Crouch A, Erba HP, and Bixby D. "Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With Inv(3)(q21.3q26.2) or T(3;3)(q21.3;q26.2); GATA2, MECOM." Clinical Lymphoma, Myeloma & Leukemia 20, no. 1 (2020): 24. https://doi.org/10.1016/j.clml.2019.09.615.

MLA (9th ed.) Citation

LE, Merz, et al. "Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With Inv(3)(q21.3q26.2) or T(3;3)(q21.3;q26.2); GATA2, MECOM." Clinical Lymphoma, Myeloma & Leukemia, vol. 20, no. 1, 2020, p. 24, https://doi.org/10.1016/j.clml.2019.09.615.